Structure Therapeutics Q1 loss widens to $76.0 million; ATM raised to $400 million
Structure Therapeutics reported a first-quarter 2026 net loss of $76.0 million, up from $46.8 million a year earlier, as research and development and G&A costs rose. The company also amended its at-the-market share sale agreement and raised the offering amount by $150 million to up to $400 million, which could add shares outstanding for shareholders.
Key points
- Q1 2026 net loss was $76.0 million, compared with $46.8 million in Q1 2025.
- R&D expenses rose to $66.5 million from $42.9 million; G&A expenses rose to $22.9 million from $13.4 million.
- Cash, cash equivalents and short-term investments were $1.5 billion at March 31, 2026, which the company expects to fund operations through the end of 2028.
- On May 7, 2026, the at-the-market offering was increased by $150 million to an aggregate offering price of up to $400 million; previously, 3,040,000 shares had been sold for gross proceeds of about $58.5 million.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.